TCL Archive In Brief: Panel Meeting Canceled; New Senior Executive Service Draws Enthusiastic Response At NCI July 13, 1979
TCL Archive Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials. October 15, 2004
TCL Archive Finally, An FY01 Appropriation For NIH; NCI’s Share $3.757 Billion, A 13.5% Raise. January 5, 2001
TCL Archive Brigham & Women’s Suspends Controversial Morcellation Study As Apparent “Difference of Opinion” with FDA Comes to Light December 5, 2014
